Dublin, July 22, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics" report to their offering. This latest report states that this strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence. The development and approval of immune checkpoint inhibitors will lower the associated toxicity of urological cancer therapies and increase their usage in typically poor-performance patients, who have a reduced functional status. Targeted treatment administration will increase patients' overall survival and enable more rounds of chemotherapy to be given. It is predicted that two new urological cancer drugs for the treatment of bladder cancer - Roche's atezolizumab and AstraZeneca's durvalumab - will achieve blockbuster status by 2022. The former is anticipated to achieve revenue of $2.5 billion in 2022, following approval from late 2016, and its uptake will be driven by a lack of targeted therapies for bladder cancer, along with increasing prevalence and clinician familiarity.
Scope - Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period? - The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market? - What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications? - How will the market shares and CAGRs of the top 20 companies compare within this therapy area? - What proportion of the key players' revenues will be attributable to urological cancers? Key Topics Covered: 1 Tables & Figures 2 Introduction 2.1 Disease Cluster Introduction 2.2 Symptoms 2.3 Etiology and Pathophysiology 2.4 Co-morbidities and Complications 2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 2.6 Treatment 3 Key Marketed Products 3.1 Overview 3.2 Zytiga (abiraterone acetate) 3.3 Xtandi (enzalutamide) 3.4 Sutent (sunitinib malate) 3.5 Votrient (pazopanib hydrochloride) 3.6 Inlyta (axitinib) 3.7 Jevtana (cabazitaxel) 3.8 Xofigo (radium Ra 223 dichloride) 3.9 Provenge (sipuleucel-T) 3.10 Opdivo (nivolumab) - Bristol-Myers Squibb 3.11 Conclusion 4 Pipeline Landscape Assessment 4.1 Overview 4.2 Pipeline Development Landscape 4.3 Molecular Targets in the Pipeline 4.4 Clinical Trials 4.5 Conclusion 4.6 Assessment of Key Pipeline Products 4.7 Conclusion 5 Multi-Scenario Market Forecast to 2022 5.1 Overall Market Size 5.2 Generic Penetration 5.3 Revenue Forecast by Molecular Target 6 Company Analysis and Positioning 6.1 Revenue and Market Share Analysis by Company 6.1.1 Pfizer - Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta? 6.1.2 Novartis - How Will Upcoming Patent Expiries Affect Urological Cancer Revenues? 6.1.3 Johnson & Johnson - How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market? 6.1.4 Astellas - What Will Become of Xtandi? 6.1.5 AstraZeneca - Will Sales Revenues Increase over the Forecast Period? 6.1.6 Bristol-Myers Squibb - How Will Cancer Immunotherapies Affect Urological Cancers? 6.2 Company Landscape 6.3 Marketed and Pipeline Portfolio Analysis 7 Strategic Consolidations 7.1 Licensing Deals 7.2 Co-development Deals 8 Appendix For more information visit http://www.researchandmarkets.com/research/v7...urological
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Oncology Drugs , Biopharmaceuticals
